FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. A modified adenovirus for the treatment of cancer has been described containing at least one of the following polypeptides covalently or non-covalently attached to the viral capsid, but not encoded by the genetically specified adenovirus vector: VFGIELMEVDPIGHLYIFAT or YLAMPFATPMEAELARRSLA, and the specified adenovirus contains a transgene encoding CD40L and/or OX40L, and additionally where the ratio of the peptide to the virus is in the range from 1 to 5 micrograms per 3E+9 viral particles. A pharmaceutical composition for the treatment of cancer has been disclosed, containing in an effective amount a modified specified adenovirus in combination with a suitable carrier. The use of this adenovirus in the manufacture of a drug for the treatment of cancer is disclosed. A method for the treatment of cancer in a patient is described, including the administration to the patient of an effective amount of the specified adenovirus or composition. EFFECT: invention expands the arsenal of drugs for the treatment of cancer.
21 cl, 13 dwg, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| VIRUS VECTOR | 2020 |
|
RU2799418C1 |
| MODIFIED ONCOLYTIC ADENO VIRUSES | 2019 |
|
RU2788638C2 |
| COMPOSITION FOR TREATING LUNG CANCER, FIRST NON-SMALL CELLS LUNG CANCER (NSCLC) | 2008 |
|
RU2526510C2 |
| ANTIGEN-BINDING PROTEIN RECOGNIZING PEPTIDE ORIGINATING FROM MAGE-A4 | 2018 |
|
RU2777074C2 |
| COATED ONCOLYTIC ADENOVIRUS FOR ANTICANCER VACCINES | 2015 |
|
RU2695375C2 |
| POLYEPITOPE ANTI-TUMOUR VACCINE STRUCTURE CONTAINING EPITOPES OF TUMOR-ASSOCIATED ANTIGENS, PHARMACEUTICAL COMPOSITION AND ITS APPLICATION FOR STIMULATING SPECIFIC ANTI-TUMOR IMMUNE RESPONSE | 2016 |
|
RU2684235C2 |
| VECTOR, CO-EXPRESSING MOLECULES FOR VACCINATION AND COSTIMULATORY MOLECULES | 2016 |
|
RU2714157C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND PROMOTER | 2015 |
|
RU2799573C2 |
| COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX CONTAINING A CELL-PENETRATING PEPTIDE, A CARGO MOLECULE, AND A TLR PEPTIDE AGONIST, FOR APPLICATION IN MEDICINE | 2017 |
|
RU2769314C1 |
| FUSION CONSTRUCTION CONTAINING CELL PENETRATING PEPTIDE, POLYEPITOPE AND TLR PEPTIDE AGONIST, INTENDED FOR TREATMENT OF CANCER | 2017 |
|
RU2807135C2 |
